Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a taste test reveal Alzheimer's before memory loss?

NCT ID NCT05888961

Diagnosis Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are studying whether taste changes can serve as an early warning sign of Alzheimer's disease. They will compare taste tests, brain responses to taste, and nutritional blood markers in four groups: healthy adults, people with mild memory complaints, people with mild cognitive impairment, and people with mild to moderate Alzheimer's. The goal is to see if taste problems appear early and could help diagnose Alzheimer's sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gustatory evoked potentials (a taste test that records brain responses to flavored solutions)
What this could lead to
If taste changes track with cognitive decline, doctors might one day use a simple taste test to spot Alzheimer's earlier, when treatments work best.
What could go wrong
This is an observational study, so it cannot prove that taste tests will work as a screening tool. Taste and brain responses vary widely between people, and the study may not find a clear link.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Person who has given oral consent. * For patients with mild to moderate Alzheimer\'s disease, the primary caregiver and the patient will be asked to provide oral consent * Person of legal age * Body Mass Index (BMI) \< 30 kg/m². * For the healthy group: absence of cognitive complaints and normal neurological assessment * Patients meeting the criteria for isolated cognitive complaint: presence of cognitive complaint but normal neuropsychological evaluation * Patients meeting diagnostic criteria for minor cognitive impairment: imaging (brain MRI) and neuropsychological assessment with a Clinical Dementia Rating (CDR) score of 0.5 * Patients meeting diagnostic criteria for mild to moderate Alzheimer\'s disease: imaging (brain MRI), neuropsychobiological criteria (consultation with neuropsychological assessment, CSF biomarkers), MMSE score ≥ 20 and CDR score of 1 or 1.5 * Fasting for at least 2 hours before GEP measurement Exclusion Criteria: * MMSE score\<15 * Known COVID-19 infection within 6 months prior to inclusion * Person not affiliated to national health insurance system * Person under a legal protection measure (curatorship, guardianship) * Person subject to a measure of legal protection * Pregnant, parturient or breastfeeding women * Subjects with a pacemaker (contraindication to bioelectrical impedance measurement) * Adult unable to express consent or to perform cognitive tests. * Active smoker (\> 4 cigarettes per day on a regular basis) * Diabetic subject (type 1 or type 2) * Subject with acute or chronic ENT disease * Treatment interfering with gustation * Brain MRI showing another cause of neurocognitive disorder (except for vascular lesions Fazekas 1 accepted)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease cognitive disorder Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    RECRUITING

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.